Peptides having immunomodulatory properties
Inventors
Jaynes, Jesse • Lopez, Henry Wilfred • Martin, George R. • YATES, Clayton • Garvin, Charles
Assignees
Publication Number
US-10413584-B1
Publication Date
2019-09-17
Expiration Date
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.
Core Innovation
The invention provides novel peptides having immunomodulatory activities in vitro and in vivo. The peptides include a striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions and can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins.
The disclosure describes peptides that are sufficiently stable in the circulation to allow for intravenous administration and pharmaceutical compositions including the subject peptides. The subject peptides find use in methods of modulating macrophage activity, in some cases as a CD206-binding agent, and in methods of treating a subject for a condition associated with chronic inflammation.
Claims Coverage
One independent claim identified. Below are the main inventive features extracted from the independent claim.
Peptide of 12 amino acid residues or less
A peptide of 12 amino acid residues or less in length comprising a sequence selected from specific disclosed sequences [sequence data omitted for safety], the peptide being an immunomodulatory peptide as claimed.
The independent claim covers short immunomodulatory peptides (≤12 amino acids) defined by specific sequences (omitted here) as the core inventive subject matter, with dependent claims and embodiments relating to pharmaceutical compositions and formulations.
Stated Advantages
Peptides have immunomodulatory activities in vitro and in vivo.
Peptides include a striapathic region that can adopt an amphipathic conformation under physiological conditions.
Peptides can specifically bind to key functional regions on signaling proteins, including pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins.
Peptides are sufficiently stable in the circulation to allow for intravenous administration.
Peptides find use in methods of modulating macrophage activity and in treating conditions associated with chronic inflammation.
Documented Applications
Methods of modulating macrophage activity, including macrophage polarization, via administration of the peptides (in some cases as CD206-binding agents).
Methods of treating a subject for conditions associated with chronic inflammation, including fibrosis and a range of inflammatory diseases listed in the specification.
Pharmaceutical compositions comprising the subject peptides and a pharmaceutically acceptable carrier, formulated for various routes including intravenous, subcutaneous, oral (enteric), topical, inhalation, intratumoral and mucosal administration.
Use of peptides in cancer treatment contexts, including combination with chemotherapeutic agents, checkpoint inhibitors, vaccination therapies, and other immunotherapies as described.
Formulations and delivery formats including liposomal, nanoparticle, and human serum albumin-containing nanoparticle formulations, and kits comprising a peptide and an additional agent for treating cancer.
Interested in licensing this patent?